Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

29 Jul 2023

Abstract excerpt

Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted therapeutic strategies. However, the dynamic interplay between IL-2/IL-2R and various immune cells and their dual roles in promoting immune activation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37516849
DOI: 10.1186/s12943-023-01826-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesPMID 37516849Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseasesSemantic proximity Read ↗

Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?Semantic proximity Read ↗

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Semantic proximity Read ↗

Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity.Semantic proximity Read ↗

CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.Semantic proximity Read ↗

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Semantic proximity Read ↗

Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology.Semantic proximity Read ↗

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.Semantic proximity Read ↗

Tumor-related interleukins: old validated targets for new anti-cancer drug developmentSemantic proximity Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.